A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
- Author:
Young-Woong WON
1
;
Jin-Hyoung KANG
;
Jung Hye KWON
;
Dong-Hoe KOO
;
Jung Hun KANG
;
Chi Hoon MAENG
;
Hee Kyung AHN
;
Sung Yong OH
;
Dae-Won LEE
;
Joohyuk SOHN
;
So Yeon OH
;
Kyung Hee LEE
;
Su-Jin KOH
;
Keun Seok LEE
;
Chan-Kyu KIM
;
Ji-Yeon KIM
;
Jun Ho JI
;
Sung-Bae KIM
;
Joo Young HA
;
Ho Young KIM
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2023;55(4):1096-1103
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods:This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results:Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion:The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.
